CSBR Overview

Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions (TOS). This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. It also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.

Wall Street analysts forecast CSBR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSBR is12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Champions Oncology Inc revenue for the last quarter amounts to 16.56M USD, decreased -2.82

Champions Oncology Inc. EPS for the last quarter amounts to -0.02 USD, decreased -106.45

Champions Oncology Inc (CSBR) has 213 emplpoyees as of March 30 2026.

Today CSBR has the market capitalization of 79.71M USD.